Scott & White Cancer Researcher Signs Contract to Help Develop Drugs
Posted on: Tuesday, 9 August 2005, 15:00 CDT
Scott & White has signed a multi-year agreement with OncoTac, based in Copenhagen, Denmark, to provide research, development and testing at the Cancer Research Institute at Scott & White.
Scott & White is one of the largest multi-specialty clinics and hospital systems in the United States. Ongoing research and education activities at Scott & White include the recently established Cancer Research Institute (CRI). Heading the CRI as its director is Arthur E. Frankel, M.D., who is the principal investigator for the research and development of cancer treatment agents using recombinant toxins under this grant.
The agreement with OncoTac provides Scott & White with quantities of anti-cancer drugs extracted from a group of substances called peptidotoxins. When developed using the company's proprietary OncoMpact(TM) technology, these drugs selectively seek out cancer cells and attach to the cell's surface. Once attached, the agent activates a toxic reaction inside the cancer cell, stopping vital cell processes. From recent work it appears these drugs may be very effective in fighting the cancer while minimizing side effects to the patient.
"OncoTac provides the compounds our research and development work needs to bring cancer treatments from bench to bedside in a shorter period of time," said Dr. Frankel. "It is a very specialized area of pharmaceutical development, with quality and safety carrying a very high premium."
Typical compounds used for Dr. Frankel's work include nontoxic forms of diphtheria and anthrax.
For more information about OncoTac, visit www.oncotac.com.
About Scott & White
Scott & White, one of the largest multi-specialty group practices in the United States, was established December 29, 1897, by Dr. Arthur C. Scott and Dr. Raleigh White Jr. Scott & White's mission is to provide personalized comprehensive high-quality health care enhanced by medical education and research. The more than 550 physicians and scientists see patients from Texas, the Southwest, the United States and many foreign countries. Scott & White's clinical education and medical research components also serve to advance medicine and discover new treatment options for patients. Learn more about Scott & White on the Internet at sw.org.
Source: Business Wire
Related Articles
- MBF Therapeutics & Lankenau Institute for Medical Research Partner To Develop Novel Drug Treatment for Companion Animal Cancers
- UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
- Receptor Logic Teams With Sanofi Pasteur to Develop T Cell Receptor Mimics (TCRm(TM)) for Vaccine Research
- View Details on the Top 20 Companies With Products in the Early Stage of Development for Non-Small-Cell Lung Cancer, Lung Cancer or Small Cell Lung Cancer
- Research Needed to Develop Generic Drugs
- Insight Medical Group Releases White Paper on Cancer Theories and Detection
- DNAPrint Genomics Selects PT-502 Lead Research Compound for Development of Drug for Treating Depression
- Taiwanese Researchers Work to Develop Anti-Fear Drug
- Researchers Working to Develop Lifesaving Drugs
- Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds